Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$17.74

-2.15 (-10.81%)

14:51
07/11/19
07/11
14:51
07/11/19
14:51

Aimmune weakness on ICER report a buying opportunity, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond attributes the 10% pullback in Aimmune shares to the publication by the Institute for Clinical and Economic Review, or ICER, of its final report on emerging desensitization treatments for peanut allergy. ICER advocates against oral immunotherapy in favor of avoidance, but Raymond said ICER's view "has been widely communicated and has changed little since last year and "ignores many key data points and perspectives." Despite ICER's stance, Raymond said his "firm belief" is that Aimmune has demonstrated AR101's clinical benefit "compellingly," that the company's Phase 3 package is approvable and the drug is set up to "enter a massive market by next year." He keeps an Overweight rating on the stock and views the weakness as an opportunity to buy.

  • 09

    Sep

  • 13

    Sep

AIMT Aimmune
$17.74

-2.15 (-10.81%)

06/19/19
PIPR
06/19/19
NO CHANGE
Target $60
PIPR
Overweight
Piper views setup for Aimmune shares as 'decidedly positive'
Following a dinner with management which included a review of the Phase 3 Artemis data, Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Aimmune Therapeutics with a $60 price target. The key takeaway from the event was the continued execution by management to successfully position AR101 for approval, Raymond tells investors in a research note. The analyst continues to see the setup on Aimmune as "decidedly positive" and he remains a buyer of the stock.
06/17/19
GSCO
06/17/19
INITIATION
Target $14
GSCO
Buy
DBV Technologies initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh started DBV Technologies (DBVT) with a Buy rating and $14 price target. DBVT is a late-stage specialty biotech company, with a proprietary technology platform that could be used to treat a range of food allergies, Suvannavejh tells investors in a research note. The analyst sees 66% upside from current share levels given the potential catalysts over the next 18 months, which include the Biologics License Applications re-filing in Q3 and FDA acceptance in Q4, a potential panel hearing in mid-2020, and likely final U.S. approval by the end of 2020. Suvannavejh sees an 85% probability of success for DBV's Viaskin Peanut and views the treatment as a more compelling option versus Aimmune's (AIMT) AR101 on overall safety and product presentation profiles.
06/10/19
CANT
06/10/19
NO CHANGE
Target $45
CANT
Overweight
Cantor has increased conviction in approvability of Aimmune's AR101
After hosting management for investor meetings in Europe and the as well the recent data presentations, Cantor Fitzgerald analyst Charles Duncan has increased conviction about the approvability of Aimmune Therapeutics' AR101 in peanut allergy. The analyst believes the "clear benefit/risk of the candidate" will fuel a "paradigm shift" in the treatment of peanut allergy for, "at least, the highest burden patient cohort" as early as Q4 of 2019. He reiterates an Overweight rating on Aimmune shares with a $45 price target.
06/04/19
JMPS
06/04/19
NO CHANGE
Target $40
JMPS
Outperform
Aimmune data firm up AR101 efficacy profile, says JMP Securities
JMP Securities analyst Liisa Bayko said data from the Phase 3 ARTEMIS study of AR101 for peanut allergy appear consistent with the Phase 3 PALISADE study, even at an earlier time point, and firm up the drug's efficacy profile. Meanwhile, safety looks "slightly better" in ARTEMIS, but this may be due to a shorter trial or differences in the patient population, Bayko added. She thinks the data support an expected MAA submission in mid-2019 and Bayko keeps an Outperform rating on Aimmune shares with a $40 price target.

TODAY'S FREE FLY STORIES

FULT

Fulton Financial

$16.31

0.11 (0.68%)

16:31
07/16/19
07/16
16:31
07/16/19
16:31
Earnings
Fulton Financial reports Q2 EPS 35c, consensus 34c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 06

    Aug

  • 07

    Aug

  • 03

    Sep

  • 05

    Sep

WAIR

Wesco Aircraft

$10.84

0.085 (0.79%)

16:30
07/16/19
07/16
16:30
07/16/19
16:30
Hot Stocks
Wesco Aircraft expans business with GKN Aerospace »

Wesco Aircraft Holdings,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
07/16/19
07/16
16:30
07/16/19
16:30
Options
Preliminary option volume of 17.5M today »

Preliminary option volume…

UBNK

United Financial

$14.07

0.05 (0.36%)

16:27
07/16/19
07/16
16:27
07/16/19
16:27
Earnings
United Financial reports Q2 EPS (6c), consensus 24c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

ERYP

Erytech Pharma

$6.69

(0.00%)

16:24
07/16/19
07/16
16:24
07/16/19
16:24
Syndicate
Erytech Pharma files to sell $100M of ADSs »

Representing ordinary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$79.57

1.05 (1.34%)

16:23
07/16/19
07/16
16:23
07/16/19
16:23
Earnings
CSX sees FY19 revenue down 1%-2% vs. prior view of growth »

CSX sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

INAP

Internap

$3.56

0.13 (3.79%)

16:22
07/16/19
07/16
16:22
07/16/19
16:22
Hot Stocks
Internap to streamline organization, initiates search for new CFO »

Internap announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNF

Fidelity National

$41.57

0.02 (0.05%)

16:21
07/16/19
07/16
16:21
07/16/19
16:21
Earnings
Fidelity National reports Q2 adjusted EPS 92c, consensus 87c »

Reports Q2 revenue $2.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 01

    Aug

  • 13

    Nov

RM

Regional Management

$26.62

-0.28 (-1.04%)

16:20
07/16/19
07/16
16:20
07/16/19
16:20
Hot Stocks
Regional Management appoints Robert Beck CFO »

Regional Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/16/19
07/16
16:20
07/16/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 16th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$15.54

-0.65 (-4.01%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Whiting Petroleum names Correne S. Loeffler CFO »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 27

    Aug

UAL

United Continental

$94.00

2.7 (2.96%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
Breaking Hot Stocks news story on CSX »

CSX Q2 CapEx down to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

BPMX

BioPharmX

$0.44

-0.0183 (-3.97%)

16:19
07/16/19
07/16
16:19
07/16/19
16:19
Hot Stocks
BioPharmX appoints Steven Bosacki COO »

BioPharmX Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCCL

China Ceramics

$0.87

(0.00%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
China Ceramics receives Nasdaq notification of non-compliance »

China Ceramics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$94.00

2.7 (2.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
United Continental reports Q2 total passenger revenue up 6.1% y/y »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VNDA

Vanda Pharmaceuticals

$13.45

-0.13 (-0.96%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Hot Stocks
Vanda Pharmaceuticals announces study results for tradipitant »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

, UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

16:18
07/16/19
07/16
16:18
07/16/19
16:18
Recommendations
Neuronetics, UnitedHealth analyst commentary  »

UnitedHealth coverage…

STIM

Neuronetics

$12.65

-0.2 (-1.56%)

UNH

UnitedHealth

$264.60

-1.31 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
Cintas sees FY20 EPS $8.30-$8.45, consensus $8.32 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

UAL

United Continental

$94.00

2.7 (2.96%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Earnings
United Continental raises FY19 adj. EPS view to $10.50-$12.00, consensus $11.33 »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/16/19
07/16
16:17
07/16/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$239.46

-3.85 (-1.58%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Earnings
Cintas reports Q4 EPS ex-items $2.07, consensus $1.93 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CSX

CSX

$79.57

1.05 (1.34%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
CSX says merchandise growth 'offset' intermodal weakness »

Chemicals increased as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 26

    Aug

  • 13

    Nov

PETX

Aratana Therapeutics

$4.94

-0.11 (-2.18%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Hot Stocks
Aratana Therapeutics shareholders vote to adopt merger with Elanco Animal Health »

Aratana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/16/19
07/16
16:16
07/16/19
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.